HIV Infected Research Studies:
- START Study (INSIGHT): This study is for HIV-Infected individuals who are antiretroviral-naïve with CD4+ count > 500 cells/mm3. The purpose of this randomized study is to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3. Duration of treatment is 3 – 6 years depending on when you enrolled into the study. Study medications provided.
- Pfizer POEM Study (A4001067): Observational study looking at the safety of maraviroc used with optimized background therapy in treatment-experienced HIV-1 infected patients.
- Pfizer Peripheral Neuropathy Pregabalin Study (A0081244 / A0081251): This Phase 3 study will compare the efficacy, safety and tolerability of pregabalin versus placebo in patients with peripheral neuropathic pain associated with HIV Infection. Duration of treatment is approximately 20 weeks.
- Viiv Healthcare – HIV/HCV/HBV Co-Infection Study (A4001098): This Phase 4 study is being conducted to evaluate the safety of maraviroc in HIV-1 infected subjects who are co-infected with Hepatitis C virus (HCV) and / or Hepatitis B virus (HBV). Duration of this study is 148 weeks.
- Pfizer NNRTI Study (A5271022): This Phase 2b study will assess the antiviral activity and safety of UK-453, 061 (750mg once daily and 1000mg once daily) compared to etravirine in combination with darunavir/ritonavir and an optimized NRTI in HIV-1 infected patients. Duration of treatment is 96 weeks.
HIV Negative Research Study:
- HIV Vaccine Study (HVTN 505): The Phase 2 trial is testing the safety and efficacy of a combination of two HIV vaccines, to see if, together, they will stimulate an immune response to HIV. Neither vaccine can cause HIV infection. For HVTN 505, investigators are seeking to enroll fully circumcised, HIV-negative (uninfected) men, 18-50 years old, who have sex with men (MSM), or transgender male to female, who have sex with men. Duration of this study is approximately 3 years.
General Population Study:
- IV Tamiflu (Oseltamivir) Study: This Phase 2/3 study will evaluate the safety of two dose levels of oseltamivir (Tamiflu) administered by intravenous infusion in the treatment of influenza. The patient will get 3 days of IV Tamiflu (minimum) and could get up to 10 days (maximum).